By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Mentice publishes the company’s interim report for the period January – March 2023

Increased sales and positive EBITDA conclude a good start for 2023.

April 27, 2023

Increased sales and positive EBITDA conclude a good start for 2023.

Significant events during the quarter

  • Two orders received from a large medical device company were announced during the quarter. The total value of these two orders together exceeded 13 MSEK.
  • Abbott Laboratories, together with Medtronic, were our largest clients in the quarter, with an order volume exceeding 17MSEK.
  • Alex Hussein was announced as our General Manager for the Americas region. Alex, prior to this position, held the position of Vice President of Sales for the Medical Device Industry USA, and he has been with Mentice since 2015.


  • Order intake amounted to 57.7 (54.4) MSEK.
  • The order book by the end of the period was 126.2 (91.4) MSEK, whereof 66.2 MSEK is revenue expected in 2023.
  • Net sales amounted to 65.0 (53.1) MSEK, an increase of 22%, whereof 15% organic.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 7.3 (-1.3) MSEK.
  • Net income for the period amounted to -1.5 (-7.4) MSEK.
  • Earnings per share (EPS) were -0.06 (-0.30) SEK.
  • Cash flow from operating activities totaled 1.2 (11.2) MSEK.

Webcast presentation of the interim report
To join the presentation, please visit

Join us today

To always stay on top within the field of medical simulation and its development subscribe to our news and resource list

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.